Rivaroxaban is an adequate treatment for thromboprophylaxis after total knee arthroplasty
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trialLancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
3148 patients who underwent total knee arthroplasty (TKA) were randomized to thromboprophylaxis using either orally administer rivaroxaban or subcutaneous injection of enoxaparin. This study assessed the efficacy of thromboprophylaxis treatment with rivaroxaban and assessed its non-inferiority to enoxaparin. The results of this study indicated that rivaroxaban was superior in comparison to enoxapa...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE